Pharmacological management of obesity in patients with type 2 diabetes

ABSTRACT

Introduction: Obesity is a growing health concern worldwide. Multiple guidelines are available to clinicians to help guide treatment of obesity.

Areas covered: In their 2016 update, the American Diabetes Association included recommendations for the use of pharmacological agents in the treatment of obesity in patients with concurrent diabetes. Five agents have been approved by the Food and Drug Administration and are recommended by guidelines for the long-term treatment of obesity: orlistat, lorcaserin, phentermine/topiramate ER, naltrexone/bupropion, and liraglutide.

Expert commentary: This article summarizes the current evidence available on the use of these agents in patients with diabetes.

KEYWORDS:

• Obesity
• type 2 diabetes
• orlistat
• lorcaserin
• liraglutide
• phentermine/topiramate ER
• naltrexone/bupropion

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

This paper was not funded.